/ JNJ
/ Earnings
Johnson & Johnson (JNJ) Reports Strong Q1 Performance
Johnson & Johnson's first-quarter results surpassed expectations with notable growth in sales and earnings.
April 15, 2025
J&J Stock Dips After $10 Billion Settlement Dismissed by Judge
Johnson & Johnson faces a significant legal setback with the dismissal of its $10 billion settlement proposal related to talc product lawsuits.
April 01, 2025
Activist Investor Starboard Acquires Stake in Band-Aid Maker Kenvue, Shares Jump
Activist hedge fund Starboard Value has reportedly taken a stake in Kenvue, sparking a pre-market stock surge.
October 21, 2024
Johnson & Johnson’s MedTech Segment Shines with Impressive Q3 Growth
Johnson & Johnson's third-quarter performance exceeded expectations, with adjusted EPS of $2.42 against an expected $2.19.
October 15, 2024
JNJ Q2 2024 Sales Surge to $22.4 Billion, Beating Expectations
Johnson & Johnson (NYSE: JNJ) reported a 4.3% increase in sales to $22.4 billion in Q2 2024, with operational growth at 6.6% and adjusted EPS rising by 10.2% to $2.82.
July 17, 2024More from The Tokenist / JNJ
Back to 
